Literature DB >> 24918548

Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.

Yibing Shan1, Kavitha Gnanasambandan2, Daniela Ungureanu3, Eric T Kim4, Henrik Hammarén3, Kazuo Yamashita5, Olli Silvennoinen3, David E Shaw6, Stevan R Hubbard7.   

Abstract

Janus kinase-2 (JAK2) mediates signaling by various cytokines, including erythropoietin and growth hormone. JAK2 possesses tandem pseudokinase and tyrosine-kinase domains. Mutations in the pseudokinase domain are causally linked to myeloproliferative neoplasms (MPNs) in humans. The structure of the JAK2 tandem kinase domains is unknown, and therefore the molecular bases for pseudokinase-mediated autoinhibition and pathogenic activation remain obscure. Using molecular dynamics simulations of protein-protein docking, we produced a structural model for the autoinhibitory interaction between the JAK2 pseudokinase and kinase domains. A striking feature of our model, which is supported by mutagenesis experiments, is that nearly all of the disease mutations map to the domain interface. The simulations indicate that the kinase domain is stabilized in an inactive state by the pseudokinase domain, and they offer a molecular rationale for the hyperactivity of V617F, the predominant JAK2 MPN mutation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24918548      PMCID: PMC4508010          DOI: 10.1038/nsmb.2849

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  39 in total

1.  Is the Ewald summation still necessary? Pairwise alternatives to the accepted standard for long-range electrostatics.

Authors:  Christopher J Fennell; J Daniel Gezelter
Journal:  J Chem Phys       Date:  2006-06-21       Impact factor: 3.488

2.  Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Authors:  Patrick J Lupardus; Mark Ultsch; Heidi Wallweber; Pawan Bir Kohli; Adam R Johnson; Charles Eigenbrot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.

Authors:  K Lindauer; T Loerting; K R Liedl; R T Kroemer
Journal:  Protein Eng       Date:  2001-01

5.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.

Authors:  Robert B Best; Xiao Zhu; Jihyun Shim; Pedro E M Lopes; Jeetain Mittal; Michael Feig; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2012-07-18       Impact factor: 6.006

6.  Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Authors:  Bhushan Nagar; Oliver Hantschel; Matthew A Young; Klaus Scheffzek; Darren Veach; William Bornmann; Bayard Clarkson; Giulio Superti-Furga; John Kuriyan
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

7.  Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling.

Authors:  Ryoko Ishida-Takahashi; Felicia Rosario; Yusong Gong; Keely Kopp; Zlatina Stancheva; Xiaohong Chen; Edward P Feener; Martin G Myers
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

8.  A simple reference state makes a significant improvement in near-native selections from structurally refined docking decoys.

Authors:  Shide Liang; Song Liu; Chi Zhang; Yaoqi Zhou
Journal:  Proteins       Date:  2007-11-01

Review 9.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

10.  Structural basis of recognition of interferon-α receptor by tyrosine kinase 2.

Authors:  Heidi J A Wallweber; Christine Tam; Yvonne Franke; Melissa A Starovasnik; Patrick J Lupardus
Journal:  Nat Struct Mol Biol       Date:  2014-04-06       Impact factor: 15.369

View more
  53 in total

1.  Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Authors:  Xiaoshan Min; Daniela Ungureanu; Sarah Maxwell; Henrik Hammarén; Steve Thibault; Ellin-Kristina Hillert; Merrill Ayres; Brad Greenfield; John Eksterowicz; Chris Gabel; Nigel Walker; Olli Silvennoinen; Zhulun Wang
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

2.  ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Authors:  Henrik M Hammarén; Daniela Ungureanu; Jean Grisouard; Radek C Skoda; Stevan R Hubbard; Olli Silvennoinen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 3.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

Review 4.  Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.

Authors:  Olli Silvennoinen; Stevan R Hubbard
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

5.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

6.  Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.

Authors:  Stephan Wilmes; Maximillian Hafer; Joni Vuorio; Julie A Tucker; Hauke Winkelmann; Sara Löchte; Tess A Stanly; Katiuska D Pulgar Prieto; Chetan Poojari; Vivek Sharma; Christian P Richter; Rainer Kurre; Stevan R Hubbard; K Christopher Garcia; Ignacio Moraga; Ilpo Vattulainen; Ian S Hitchcock; Jacob Piehler
Journal:  Science       Date:  2020-02-07       Impact factor: 47.728

7.  Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.

Authors:  David E Puleo; Kaury Kucera; Henrik M Hammarén; Daniela Ungureanu; Ana S Newton; Olli Silvennoinen; William L Jorgensen; Joseph Schlessinger
Journal:  ACS Med Chem Lett       Date:  2017-05-17       Impact factor: 4.345

8.  JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.

Authors:  Friederike Pastore; Aishwarya Krishnan; Henrik M Hammarén; Olli Silvennoinen; Benedict Yan; Ross L Levine
Journal:  Blood Adv       Date:  2020-09-22

9.  The Structural Basis for Class II Cytokine Receptor Recognition by JAK1.

Authors:  Ryan Ferrao; Heidi J A Wallweber; Hoangdung Ho; Christine Tam; Yvonne Franke; John Quinn; Patrick J Lupardus
Journal:  Structure       Date:  2016-04-28       Impact factor: 5.006

Review 10.  Structural Basis for the Non-catalytic Functions of Protein Kinases.

Authors:  Jennifer E Kung; Natalia Jura
Journal:  Structure       Date:  2016-01-05       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.